CohBar (CWBR) – Press Releases
-
CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
-
CohBar Reports Second Quarter 2023 Financial Results
-
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (
-
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunoth
-
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunoth
-
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
-
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
-
CohBar Announces Reverse Stock Split
-
CohBar Announces Reverse Stock Split
-
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
-
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
-
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
-
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
-
CohBar to Participate at Upcoming Conferences in June 2022
-
CohBar to Participate at Upcoming Conferences in June 2022
-
CohBar to Present at the H.C. Wainwright Global Investment Conference
-
CohBar to Present at the H.C. Wainwright Global Investment Conference
-
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal
-
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal
-
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
-
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
-
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
-
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
-
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
-
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
-
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
-
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
-
CohBar Announces Changes to its Board of Directors and R&D Leadership
-
CohBar Announces Changes to its Board of Directors and R&D Leadership
-
CohBar’s CEO to Participate in Upcoming BIO Webinar
-
CohBar’s CEO to Participate in Upcoming BIO Webinar
-
CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update
-
CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update
-
CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021
-
CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021
-
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
-
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
-
CohBar Announces Proposed Public Offering of Common Stock and Warrants
-
CohBar Announces Proposed Public Offering of Common Stock and Warrants
-
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
-
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
Back to CWBR Stock Lookup